Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theraphage COVID-19 intranasal UVLP vaccine
- Development stage
- Preclinical
- Lead developer
- Theraphage
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The Theraphage COVID-19 intranasal UVLP vaccine is a preclinical vaccine candidate developed by the Theraphage research laboratory at the University of Waterloo. This vaccine utilizes a Universal Virus-Like Particle (UVLP) platform, engineered using bacteriophage-based technology (iPhAGE system). It is designed for intranasal administration to specifically elicit both mucosal immunity in the respiratory tract and systemic immunity against SARS-CoV-2. By mimicking the structural characteristics of the virus without containing infectious genetic material, the UVLP aims to provide a robust and targeted immune response.
- Other names
- intranasal UVLP vaccineCOVID-19 vaccine (intranasal UVLP)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Theraphage COVID-19 intranasal UVLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theraphage COVID-19 intranasal UVLP vaccine.